<DOC>
	<DOC>NCT00516438</DOC>
	<brief_summary>The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with topotecan chemotherapy in patients with advanced solid tumours</brief_summary>
	<brief_title>Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
	<criteria>Histological or cytological diagnosis of advanced solid tumour for which no suitable effective therapy exists; Evaluable disease Adequate bone marrow, hepatic and renal function Any chemotherapy, radiotherapy ( except palliative), endocrine or immunotherapy within 4 weeks prior to entry; major surgery with 4 weeks of entering the study Heavily pre treated patient &gt; 2 previous chemotherapy regimens for metastatic disease Coexisting active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>malignant solid tumours</keyword>
	<keyword>Poly(ADP ribose)</keyword>
	<keyword>polymerases</keyword>
</DOC>